why choose us

First received: November 09, 2022

Clinical Trial: A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Angelman Syndrome

Study Type: INTERVENTIONAL


Official Title: A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelma

Brief Summary: This is a two-part, Phase IIa, multicenter, 12-week, open-label study.Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.

Read more